5 Key Takeaways
-
1
Biogen has acquired Apellis Pharmaceuticals, enhancing its portfolio with two commercial drugs and expanding into nephrology.
-
2
Apellis is now a wholly owned subsidiary of Biogen, following a successful tender offer for approximately 82.4% of its shares.
-
3
Apellis shareholders will receive $41 per share in cash, plus a contingent value right worth up to $4 per share based on future sales.
-
4
The acquisition is expected to boost Biogen's earnings growth and become accretive to non-GAAP diluted earnings per share by 2027.
-
5
Biogen aims to leverage Apellis' infrastructure to support the future launch of felzartamab for kidney transplant patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
